Recent pharmacogenomic studies profiled large panels of cancer cell lines against hundreds of approved drugs and experimental chemical compounds. The overarching goal of these screens is to measure sensitivity of cell lines to chemical perturbation, correlate these measures to genomic features, and thereby develop novel predictors of drug response. However, leveraging this valuable data is challenging due to the lack of standards for annotating cell lines and chemical compounds, and quantifying drug response. Moreover, it has been recently shown that the complexity and complementarity of the experimental protocols used in the field result in high levels of technical and biological variation in the in vitro pharmacological profiles. There is therefore a need for new tools to facilitate rigorous comparison and integrative analysis of largescale drug screening datasets. To address this issue, we have developed PharmacoDB (pharmacodb.pmgenomics.ca), a database integrating the largest pharmacogenomic studies published to date. Here, we describe how the curation of cell line and chemical compound identifiers maximizes the overlap between datasets and how users can leverage such data to compare and extract robust drug phenotypes. PharmacoDB provides a unique resource to mine a compendium of curated pharmacogenomic datasets that are otherwise disparate and difficult to integrate.
INTRODUCTION
Cancer has emerged as one of the principal causes of mortality in the 21st century (1) . It is a collection of related diseases with widely different prognosis and response to therapy (2) . This heterogeneity poses challenges for treatment, as patients with the same diagnosis often have different responses to treatment and may develop resistances at different rates (3) . The genesis, progression, and response to pharmacotherapy of cancer is largely determined by the molecular state and features of the tumour cells (4) . This observation spurred the development of the field of pharmacogenomics to study the relationships between genomic, transcriptomic and proteomic features of cancer cells and their response to treatment with small molecule compounds.
Immortalized cancer cell lines are the most widely-used models to study response of tumors to anticancer compounds (5) . In addition to being comprehensively profiled at the molecular level, cancer cell lines can be cultured to conduct high-throughput drug screening studies, where large panels of compounds are screened for their efficacy of halting the growth or killing molecularly distinct cancer tumour models (6) . Over the past decade, several large studies combining high-throughput in vitro drug screening with molecular profiling of cancer cell lines have been published (7) (8) (9) (10) (11) (12) (13) . Recognizing that the molecular diversity of cancer cannot be faithfully represented by small panels of cell lines, these studies have assembled large panels of hundreds to over a thousand cell lines and profiled them at the molecular and pharmacological levels. These valuable data have been publicly released via well-established repositories, including NCBI Gene Expression Omnibus (14) and EMBL-EBI European Genome-phenome Archive (15) , and institutional websites.
Recent computational approaches have leveraged these high-throughput pharmacogenomic data in a wide range of biomedical applications. Drug screening on hundreds of cell lines has enabled more comprehensive discovery of molecular features associated with drug response across cancer types and in specific tissues (16) . Transcriptomic changes due to chemical perturbations in cell lines were intensively used to match drug to disease with the aim to define new indications for existing drugs, also referred to as drug repurposing (17, 18) .
Pharmacogenomic data have been used to develop new classification schemes for chemical compounds in order to determine or refine their mechanism of action (19, 20) . In vitro drug screening data combined with single-cell RNA-sequencing profiles have opened new avenues of research for the rational discovery of synergistic drug combinations in renal cell carcinoma (21) . Recent studies have investigated the relevance of in vitro and in vivo drug screening for precision medicine (22) (23) (24) . These examples clearly demonstrate the value of the pharmacogenomic data for basic and translational cancer research.
The main limitation of the majority of published pharmacogenomic studies is that they are restricted to the analysis of single datasets. This is primarily due to inconsistent annotations of cell lines and compounds, which prevents direct comparison between datasets (25) . Metaanalysis of pharmacogenomic data is further hindered by the lack of standards for statistical modeling of drug dose-response curves and subsequent summarization into drug sensitivity measures (25) (26) (27) (28) . However, joint analysis of independent datasets holds the potential to improve robustness of research outputs against variations in the complex experimental protocols used in high-throughput drug screening (29, 30) . To address these issues we developed PharmacoDB, the first database integrating multiple high-throughput pharmacogenomic datasets that have been recently released (Table 1 ; Supplementary Figure   1A ). PharmacoDB provides an intuitive interface to search and explore these datasets ( Figure   1A analyze molecular features and drug dose-response curves (31) . Here, we describe the content of our integrative pharmacogenomic database, the curation process, and its web-interface.
DATA COLLECTION AND DATABASE CONTENT

Pharmacogenomic studies
PharmacoDB seeks to include the largest published studies investigating the viability response of human cancer cell lines to chemical compound treatment. To date, we have curated 7 major studies: The Cancer Cell Line Encyclopedia (CCLE) (9) , Genomics of Drug Sensitivity in Cancer (GDSC) (7, 8) , Genentech Cell Screening Initiative (gCSI) (11, 12) , the Cancer Therapeutic Response Portal (CTRP) (19, 32) , the Oregon Health and Science University (OHSU) Breast Cancer Screen by Dr. Joe Gray's lab (GRAY) (10, 33) , the Institute for Molecular Medicine Finland cell viability screen (FIMM) (13) , and the University Health Network (Toronto) breast cancer screen (UHNBreast) (29) . For each study, we downloaded the cell line and compound annotations available with the original publications of the study, either through the journal website or dedicated portals for data sharing made available by the study authors (Table 1; Supplementary Figure 1A ; Supplementary Methods).
Annotation of cell lines and chemical compounds
We performed semi-automated curation of all the cell line and compound identifiers with the goal of discovering and maximizing the overlap between the datasets. First, we looked for exact case-insensitive matches of the identifiers used in the dataset undergoing curation to already curated unique identifiers, if applicable. Second, for all remaining compounds and cell lines, a partial matching algorithm was used to generate candidate unique identifier matches for each identifier used in the study. These candidate matches were manually reviewed to find the correct match for all compounds and cell lines which had a matching unique identifier. Third, for the subset of compounds for which there was no match using the compound names, we used any other provided compound annotations such as the SMILES, InchiKey or PubChem identifier to match them with identifiers available for previously curated compounds. Lastly, for compounds missing all of the SMILES, InchiKey and other chemical identifiers, the PubChem database was accessed through the WebChem R package (version 0.2) and queried by a compound's name as described below. If it was possible to retrieve the identifiers of these compounds, then the third step was repeated to find possible matches with previously curated compounds. For cell lines which had no correct matches in the second step, Cellosaurus (34) was queried to generate candidate cell name synonyms, and matching was attempted with current unique identifiers. If at the end of these four steps there remained any cell line or compound names that were not matched, a new unique, human interpretable identifier was created based on the name from the dataset currently undergoing curation. This curation process maximized the overlap between datasets (Figure 2) , and established links to external databases using Pubchem identifiers for compounds and Cellosaurus accession identifiers for cell lines. Overall, we identified 1,691 unique cell lines from 41 tissue sources ( Figure 3A ) and 759 unique compounds with 673 associated targets ( Figure 3B ).
Our curation process substantially increased the overlap across all the datasets compared to an exact matching procedure for both cell lines and compounds ( Figure 4 ). While some intersections increased only modestly due to similar identifiers being used in the original studies, the benefit was substantial for others. For example, the intersection of compounds tested in GDSC1000 and CTRPv2 more than tripled, from 27 to 90 (Figure 4 ). While many of the newly matched identifiers differed only in capitalization or hyphenation, computational approaches to mapping identifiers which ignore these differences would be insufficient. These approaches would fail to match certain cases, such as the matching of compound names AZD6244 and Selumetinib, and would also cause mismatches, as for example for the distinct cell lines KMH-2 and KM-H2, which are respectively a Hodgkin's lymphoma cell line and a thyroid gland carcinoma. Differences in naming conventions often create difficulties and confusion for researchers who wish to integrate data from across different studies, and the curation done in PharmacoDB aims to alleviate this barrier to leveraging these valuable pharmacogenomics studies.
Annotation of drug targets
To obtain a comprehensive collection of target proteins for the compounds included in PharmacoDB, the union of known drug-target associations from four distinct data sources was integrated into the database. The CTRPv2 study released curated annotations of the protein targets for compounds (19) . Additional drug target annotations were retrieved programmatically from the Drug Repurposing Hub (35) , DrugBank (36) , and ChEMBL (37) . For DrugBank, we retrieved the gene symbol for each target using UniProt.ws (version 2.16.0). For ChEMBL, we used the Web API to retrieve gene symbols for the protein targets, subsequently linked to the appropriate GeneCard (38, 39) . As expected, we found tyrosine kinases to be the targets with the most associated compounds: KDR (also known as the vascular endothelial growth factor receptor 2, VEGFR-2), KIT, FLT1/3/4, and PDGFRA/B ( Figure 3B ). These genes are the targets of multiple kinase inhibitors, including linifanib, foretinib, tivozanib and axitinib that have been extensively tested across datasets (over 1,800 drug dose-response curves for each drug).
HDAC, CDK and PI3K are also the most prevalent targets in PharmacoDB ( Figure 3B ).
DATABASE ORGANIZATION AND WEB-INTERFACE Database implementation
All of the data is stored in a MySQL database running the default MyISAM database engine and with indexing configured on all tables in order to speed up queries (database schema in Supplementary Figure 2) . The web interface is implemented using Ruby (version 2.4.1) and Ruby on Rails (version 5). To provide a smooth navigation experience, the front-end is rendered on the server and performance is optimized with use of Turbolinks (version 5.0), which does selective updates and contributes to faster page load times. All charts were produced using d3.js (version 3), a JavaScript library tailored to produce dynamic and interactive data visualizations using SVG, HTML5, and CSS web standards. Every plot generated on PharmacoDB is available for download in the SVG vectorized graphics format and the data used to generate the plot are exportable as spreadsheets.
Search Interface
Often, biomedical researchers interested in leveraging pharmacogenomic data are investigating a specific biological question about a given cell line, tissue, drug, or target. PharmacoDB is 
Search by synonyms
The same cell line, tissue, or compound entity is often known by several names, which are often used interchangeably in the literature. As described above, semi-manual curation of datasets in PharmacoDB was done to map the synonyms used in each dataset to a unique human interpretable identifier. However, as each user may be more or less familiar with a specific synonym for a given compound or cell line, PharmacoDB was implemented such that it is possible to search for a compound, tissue or cell line by any of the synonyms collected in the curation process. This means that if a researcher is familiar with the name of a compound used in the CTRPv2 dataset, for example, they can use this identifier to find experiments with the same compound across other datasets. The synonyms encountered include different spelling or punctuation as well as completely different names, and enable a more natural interface with the database. Currently, there are 4,162 different synonyms used to refer to the 1,691 cell lines, 980 synonyms to refer to the 759 compounds, and 184 synonyms for the 41 tissues in PharmacoDB.
Explore Interface
Complementing the Search interface, the explore page serves as a gentle entry point for new users attempting to navigate PharmacoDB. It facilitates discovery of content by presenting to the user all the entities aggregated in the database. User interaction with the explore page occurs in a series of filtering steps to find the entity or experiment of interest. Depending on which selections users make, unrelated annotations are filtered out until they make a selection corresponding to a single query of the database This will allows the user to quickly navigate through the large collection of entities while having a complete picture of all the targets, tissues, compounds and drugs included in PharmacoDB.
Profile Pages
If a search query for a single entity is entered into the search bar, or if an entity is selected in the explore page, the user is redirected to a profile page. This page is designed to provide the user with a comprehensive view of all the data available for the entity of interest ( 
Molecular data
In addition to cell line viability screens, the pharmacogenomic datasets included in PharmacoDB include extensive molecular profiling. We recently released the PharmacoGx package (31) to facilitate the analysis of the relationships between the pharmacological and molecular data for the purposes of biomarker discovery (30) and drug repurposing (20) . The reprocessing of pharmacological data and the extensive curation of identifiers done for PharmacoDB has been fully integrated into PharmacoSet (PSet) R objects released with the PharmacoGx platform.
While PharmacoDB does not contain molecular data, a PSet object has been created and linked to from each dataset profile page (Supplementary Figure 1A) . To facilitate finding molecular data for a specific cell line, a table describing the availability of molecular profiles in
PharmacoGx is available at the bottom of each cell line profile page. The link between PharmacoDB and PharmacoGx enables bioinformaticians to use PharmacoDB as an entry point for their pharmacogenomic analysis, and allows them to leverage the extensive curation done in PharmacoDB.
Drug dose-response curves
Searching for a cell line-drug pair or selecting a cell line with a drug through the explore page will redirect to a page displaying the dose-response data found across all datasets. The page includes a plot of the measured viability values and a Hill Slope curve fit to the measured data ( Figure 6A ; Supplementary Methods), followed by a table of summary statistics commonly used to summarize the sensitivity/resistance of the cell line to the given compound ( Figure 6B ). Each curve plotted on the graph can be hidden and shown by clicking on its entry in the legend. We used PharmacoGx (31) to normalize and reprocess all cell viability data with a uniform pipeline to remove any biases between datasets introduced by computational aspects such as choice of Hill Slope model, curve fitting algorithms, or inconsistent calculations of summary statistics between studies (Supplementary Methods). Given the lack of consensus regarding the best way to summarize drug dose-response curve, we computed a compendium of summary metrics for the response of the cell line to the treatment with the compound, including the common IC50 (dose of 50% inhibition of cell viability), EC50 (dose at which 50% of the maximum response is observed), Area Above Curve (AAC), Einf (maximum theoretical inhibition), and the recent drug sensitivity score (DSS) (40) . Hovering over a value in the summary measures table will display on the plot a visualization of the procedure used to calculate the summary statistic. As ther e is no consensus as to the optimal metric for summarizing the information contained in the dose response curve (41) . The IC50 and EC50 metrics focus on the potency of the compound, the Emax on the efficacy, and the AAC and DSS integrate both potency and efficacy. These metrics are presented together on PharmacoDB, and a visualization of method of calculating them is displayed directly on the drug dose-response curve to aid in making an informed decision of the correct measure to use for a given experiment or specific biological question of interest.
USER ACCESS TO DATA, CODE AND FEEDBACK
Programmatic data access
PharmacoDB exposes its data through an Application Programming Interface (API), enabling users to programmatically interact with the application. The API is RESTful (Representational State Transfer), meaning that all application resources are made available using a predefined set of stateless operations, in this case being HTTP verbs such as GET, POST, DELETE. No authentication keys, or tokens, are currently needed in order to access the API. The API has been implemented using the Go programming language, and Gin HTTP web framework has been used for routing. All queries are made using HTTP GET requests, and all results are returned in JSON format by default. The base URL used for all queries is https://api.pharmacodb.com/v1/. The end "/v1" corresponds to the version of the API being queried. This version can be changed to any of the API versions that are, or will be, released by PharmacoDB. Whenever a newer version is released, both the API and the MySQL database of the previous version are frozen and open for use at that version URL. Furthermore, breaking changes will only be introduced in a newer version. Hence, no application that integrates or uses PharmacoDB data will break, or be affected by breaking changes. All the data in PharmacoDB are publicly available via the API. Additionally, a dump of the SQL database is available for download from the front page and R objects for all the pharmacogenomic datasets are available via the PharmacoGx R/Bioconductor package (31).
Code and documentation
The PharmacoDB code is open-source and publicly available through the PharmacoDB GitHub repository (github.com/bhklab/PharmacoDB) under the GPLv3 license. The documentation is available in the web-application as video and textual descriptions of all the entities and search queries in PharmacoDB. These include descriptions of the dataset, tissue, cell line, target, and drug/compound pages. Tutorial on how to perform more complex queries, such as displaying a drug dose-response curve and intersecting two or three datasets, is also described in details in the Documentation page of PharmacoDB.
Feedback
Our web-application provides an easily accessible, optionally anonymous contact mechanism for providing feedback on all aspects of PharmacoDB. Users can suggest corrections to annotations by clicking on the feedback icon accessible on the left of every profile page. The fields in the "Contact Us" page are then prefilled with data relevant to the annotation in question.
The GitHub API is then used to automatically file user suggestions and feedback as issues in the GitHub Issue Tracker at our repository (github.com/bhklab/PharmacoDB). This allows for full transparency regarding the reliability of data in the database and enables the community to fully assess and correct any missing information.
SUMMARY AND FUTURE DIRECTIONS
PharmacoDB is the first database providing a comprehensive resource to search and explore the largest pharmacogenomic studies released to date. By combining rigorous curation of identifiers across the published pharmacogenomic datasets with comprehensive search and visualizations of the pharmacological data, PharmacoDB allows researchers to quickly access the data available to answer their biological questions of interest. It provides an interface to query for specific drug dose-response curves, and easily find the largest possible intersection between datasets.
As current pharmacogenomic datasets continue to expand and new ones are published, the number of cell lines screened with compounds will increase, opening new avenues of research for meta-analysis in biomarker discovery and other applications. In this setting, PharmacoDB will provide a unique resource where researchers can quickly mine the large amount of data generated by these high-throughput drug screening studies. Moreover, given the recent activity in the pharmacogenomic field, new statistical approaches are being developed to better model and summarize drug dose-response curves. Recently, Hafner et al. published the growth rate inhibition 50 (GR50) metric to robustly quantify drug response by accounting for the different proliferation rate of each cancer cell lines (42) , and showed an increase in consistency across datasets (43) . Although this method and others may require data that are not always available for all datasets (e.g., proliferation rate of each cell lines for GR50) we are committed to implement them to provide users with the opportunity to select the most relevant readout for their specific application. In addition to datasets measuring cell viability, we also plan to update PharmacoDB with pharmacogenomic datasets reporting the transcriptional changes due to chemical perturbation, such as the Connectivity Map (17) and the L1000 (44) datasets. The combination of drug sensitivity and perturbation data would allow users to study deeper the relationship between the molecular state of cancer cell lines and their response to compound perturbations (20) . The flexibility of PharmacoDB will enable continuous update of the pharmacogenomic datasets, and facilitate the analysis of these valuable data by the scientific community.
SUPPLEMENTARY DATA Supplementary Methods reporting the sources of pharmacogenomic datasets, and describing the fitting of the drug dose-response curves and the application programming interface (API).
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Fitting drug dose-response curves
The rate-limiting step in the killing of susceptible cancer cells by an anti-cancer drug is assumed to be the binding of a target receptor R to n molecules of a drug D, and the free drug molecules and unbound target are assumed to be in thermodynamic equilibrium with the bound drug-target complex:
By the Law of Mass Action, this equilibrium is characterized by an equilibrium constant K satisfying the equation
where brackets around a variable name denote the concentration of the molecule it represents. It then follows that the fraction f of receptors bound to ligands is given by
+ K Since this binding is the rate-limiting step in the killing of cancer cells, the fraction y(x) of susceptible cancer cells killed by a concentration x of the drug is approximately equal to the fraction of unbound receptors 1 f :
We define EC 50 = n p K and interpret it as the concentration of the drug needed to have half of the target receptors bound at equilibrium. We also assume that a fraction E 1 of the cancer cells are not susceptible to the drug at all. This leads to our final equation
) HS where y(x) = 0 denotes death of all treated cells, y(x) = 1 denotes no effect of the drug dose, EC 50 is the concentration at which y(EC 50 ) = 1 2 , and HS is a parameter describing the cooperativity of binding. HS < 1 denotes negative binding cooperativity, HS = 1 denotes noncooperative binding, and HS > 1 denotes positive binding cooperativity. This is the basic mathematical structure that was posited to underlie the dose-response data observed in the study. Consequently, median cellular viability data from all datasets was fit by means of leastsquares regression to equations of this type. To ensure robustness of the curve-fitting algorithms, The inclusion of this parameter makes comparison of dose-response curves problematic. With its inclusion, the viability of the cell line in the absence of any drug becomes
As a result, the viability measures of different drug-cell line combinations are normalized differently, and direct comparison of viability predictions from different dose-response curves is no longer appropriate. The IC 50 values they reported, however, were simply the concentrations at which their fitted curves reached viability reduction of 50% of cellular viability. The end result was a reported IC 50 value that assumed normalization of viability data to the negative control associated with a curve fitted assuming normalization of viability data to a reference level that was most consistent with the observed data. The IC 50 values published in the paper's supplementary information thus represented viability reduction by a fraction that varied from cell line to cell line.
In GDSC, the following five-parameter model was used:
) HS ) S However, since the E 0 parameter is fixed by controls, their curve can be represented as
This parameter accounts for the presence of an antagonistic binding of the drug, and introduces asymmetry into the theoretical log dose-response curve. The extra parameter, known as the "Schild slope", allows the dose-response curve to be non-monotonic. While this parameter is well-founded biologically, we chose not to use it in our own dose-response curves. As only medians of technical replicates are available for CCLE, using a 4-parameter model would have increased our susceptibility to overfitting noise in the sparse dose-response curves. Furthermore, we only rarely observed the non-monotonicity that necessitates the inclusion of a Schild slope parameter in a very small fraction of dose-response curves. For these reasons, we ultimately chose to use our simpler 3-parameter model to compare the dose-response curves from the GDSC and CCLE datasets. 
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Supplementary Figure 1 : Flow diagrams describing (A) the external resources used to populate PharmacoDB; and (B) the "Search" and "Explore" interfaces to query PharmacoDB.
